Abstract
Inhibitors of thymidylate synthase (TS) play an essential role in the pharmacological management of several tumors. Two antifolates, Raltitrexed and Pemetrexed, are licensed anticancer drugs, with Pemetrexed, unlike Raltitrexed, undergoing further intense clinical development. Other antifolate TS inhibitors, recently/currently tested in clinical studies, that show encouraging anticancer activities are Plevitrexed, GW7904L and Nolatrexed. A new prospect among antifolates, demonstrating a very desirable pattern of pharmacological properties, is BGC 945 that showed promising antitumor activities and has been nominated for clinical development. In this paper, apart from reviewing their biochemical and pharmacological properties, up-to-date characteristics of clinical development of all the mentioned agents are presented. In addition, trends and perspectives for developing improved antifolate inhibitors of TS and future drugs are discussed. Drug resistance is the main barrier to more effective treatment of cancers with antifolates; therefore, mechanisms of antifolate resistance and currently applied approaches to overcome it are also pointed out in the review.
Keywords: Thymidylate synthase (TS), inhibitors, antifolates, anticancer drugs, Thymidylate synthase, TS ThyA, deoxyuridylate, dUMP, 5,10-methylene-5,6,7,8-tetrahydrofolate, mTHF, thymidylate, dTMP, 7,8-dihydrofolate, DHF, 5-fluorouracil, FUra, 5-fluoro-2'-deoxyuridylate, (FdUMP), N(4)-hydroxy-dCMP, 5-fluoro congener, N(4)-OH-FdCMP, Raltitrexed, CB3717, PDDF, antifolate analogue, phase III Pan European Trial in Adjuvant Colon Cancer-1 (PETACC-1), malig-nant pleural mesothelioma, Pemetrexed, ALIMTA, MTA, LY231514, antifolate, dihydrofolate re-ductase, DHFR, aminoimidazole carboxamide ribonu-cleotide formyltransferase, Aicarft, lometrexol, PLEVITREXED, GW1843, NOLATREXED, BGC 945
Mini-Reviews in Medicinal Chemistry
Title: Antifolate Inhibitors of Thymidylate Synthase as Anticancer Drugs
Volume: 10 Issue: 13
Author(s): A. Jarmula
Affiliation:
Keywords: Thymidylate synthase (TS), inhibitors, antifolates, anticancer drugs, Thymidylate synthase, TS ThyA, deoxyuridylate, dUMP, 5,10-methylene-5,6,7,8-tetrahydrofolate, mTHF, thymidylate, dTMP, 7,8-dihydrofolate, DHF, 5-fluorouracil, FUra, 5-fluoro-2'-deoxyuridylate, (FdUMP), N(4)-hydroxy-dCMP, 5-fluoro congener, N(4)-OH-FdCMP, Raltitrexed, CB3717, PDDF, antifolate analogue, phase III Pan European Trial in Adjuvant Colon Cancer-1 (PETACC-1), malig-nant pleural mesothelioma, Pemetrexed, ALIMTA, MTA, LY231514, antifolate, dihydrofolate re-ductase, DHFR, aminoimidazole carboxamide ribonu-cleotide formyltransferase, Aicarft, lometrexol, PLEVITREXED, GW1843, NOLATREXED, BGC 945
Abstract: Inhibitors of thymidylate synthase (TS) play an essential role in the pharmacological management of several tumors. Two antifolates, Raltitrexed and Pemetrexed, are licensed anticancer drugs, with Pemetrexed, unlike Raltitrexed, undergoing further intense clinical development. Other antifolate TS inhibitors, recently/currently tested in clinical studies, that show encouraging anticancer activities are Plevitrexed, GW7904L and Nolatrexed. A new prospect among antifolates, demonstrating a very desirable pattern of pharmacological properties, is BGC 945 that showed promising antitumor activities and has been nominated for clinical development. In this paper, apart from reviewing their biochemical and pharmacological properties, up-to-date characteristics of clinical development of all the mentioned agents are presented. In addition, trends and perspectives for developing improved antifolate inhibitors of TS and future drugs are discussed. Drug resistance is the main barrier to more effective treatment of cancers with antifolates; therefore, mechanisms of antifolate resistance and currently applied approaches to overcome it are also pointed out in the review.
Export Options
About this article
Cite this article as:
Jarmula A., Antifolate Inhibitors of Thymidylate Synthase as Anticancer Drugs, Mini-Reviews in Medicinal Chemistry 2010; 10 (13) . https://dx.doi.org/10.2174/13895575110091211
DOI https://dx.doi.org/10.2174/13895575110091211 |
Print ISSN 1389-5575 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5607 |
Call for Papers in Thematic Issues
Bioprospecting of Natural Products as Sources of New Multitarget Therapies
According to the Convention on Biological Diversity, bioprospecting is the exploration of biodiversity and indigenous knowledge to develop commercially valuable products for pharmaceutical and other applications. Bioprospecting involves searching for useful organic compounds in plants, fungi, marine organisms, and microorganisms. Natural products traditionally constituted the primary source of more than ...read more
Computational Frontiers in Medicinal Chemistry
The thematic issue "Computational Frontiers in Medicinal Chemistry" provides a robust platform for delving into state-of-the-art computational methodologies and technologies that significantly propel advancements in medicinal chemistry. This edition seeks to amalgamate top-tier reviews spotlighting the latest trends and breakthroughs in the fusion of computational approaches, including artificial intelligence (AI) ...read more
Mitochondria as a Therapeutic Target in Metabolic Disorders
Mitochondria are the primary site of adenosine triphosphate (ATP) production in mammalian cells. Moreover, these organelles are an important source of reactive oxygen and nitrogen species in virtually any nucleated cell type. The modulation of a myriad of cellular signaling pathways depends on the mitochondrial physiology. Mitochondrial dysfunction is observed ...read more
Natural Products and Dietary Supplements in Alleviation of Metabolic, Cardiovascular, and Neurological Disorders
Metabolic disorders like diabetes, obesity, inflammation, oxidative stress, cancer etc, cardiovascular disorders like angina, myocardial infarction, congestive heart failure etc as well as neurological disorders like Alzheimer?s, Parkinson?s, Epilepsy, Depression, etc are the global burden. They covered the major segment of the diseases and disorders from which the human community ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Recent Advances on Radionuclide Labeled Hypoxia-Imaging Agents
Current Pharmaceutical Design Versatile Applications of microRNA in Anti-Cancer Drug Discovery: From Therapeutics to Biomarkers
Current Drug Discovery Technologies Drug Design Studies of the Novel Antitumor Targets Carbonic Anhydrase IX and XII
Current Medicinal Chemistry Mining Sarcomas by Proteomics Approaches: Ewing Sarcoma on the Spotlight
Recent Patents on Biotechnology Meet Our Editorial Board Member
Current Stem Cell Research & Therapy Mucoadhesive Polymers for Delivery of Drugs to the Oral Cavity
Recent Patents on Drug Delivery & Formulation Patent Selections
Recent Patents on Anti-Cancer Drug Discovery The Function of the Selective Inhibitors of Cycloxygenase 2
Mini-Reviews in Medicinal Chemistry Protein Phosphatase 1 and Its Complexes in Carcinogenesis
Current Cancer Drug Targets The History of the HSV Amplicon: From Naturally Occurring Defective Genomes to Engineered Amplicon Vectors
Current Gene Therapy Therapeutic Prospects for Parathyroid Hormone and Parathyroid Hormone Analogs
Current Medicinal Chemistry - Immunology, Endocrine & Metabolic Agents Current Understanding of HSP90 as a Novel Therapeutic Target: An Emerging Approach for the Treatment of Cancer
Current Pharmaceutical Design Metformin Treatment Sensitizes Human Laryngeal Cancer Cell Line Hep- 2 to 5-Fluorouracil
Clinical Cancer Drugs An Insight of Molecular Mechanisms and Patents of Biomarkers of Human Papilloma Virus Associated with Cancer : A Review
Recent Patents on Biomarkers Histopathological Determinants of Tumor Resistance: A Special Look to the Immunohistochemical Expression of Carbonic Anhydrase IX in Human Cancers
Current Medicinal Chemistry Peptides to Target Tumor Vasculature and Lymphatics for Improved Anti-Angiogenesis Therapy
Current Cancer Drug Targets Wnt/β-catenin Antagonists: Exploring New Avenues to Trigger Old Drugs in Alleviating Glioblastoma Multiforme
Current Molecular Pharmacology Big Data to Knowledge: Application of Machine Learning to Predictive Modeling of Therapeutic Response in Cancer
Current Genomics Renaissance of the Biologically Active Vitamin A Derivatives: Established and Novel Directed Therapies for Cancer and Chemoprevention
Current Pharmaceutical Design Thirty Years of Polyamine-Related Approaches to Cancer Therapy. Retrospect and Prospect. Part 2. Structural Analogues and Derivatives
Current Drug Targets